These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9779912)

  • 1. Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients.
    Sherr JD; Kelly DL
    Psychiatr Serv; 1998 Oct; 49(10):1355-7. PubMed ID: 9779912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions.
    Wassef AA; Winkler DE; Roache AL; Abobo VB; Lopez LM; Averill JP; Mian AI; Overall JE
    Am J Psychiatry; 2005 Feb; 162(2):330-9. PubMed ID: 15677599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic impact of replacing divalproex sodium with valproic acid.
    Cranor CW; Sawyer WT; Carson SW; Early JJ
    Am J Health Syst Pharm; 1997 Aug; 54(15):1716-22. PubMed ID: 9262743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses.
    Puryear LJ; Kunik ME; Workman R
    J Geriatr Psychiatry Neurol; 1995 Oct; 8(4):234-7. PubMed ID: 8561838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
    Horne RL; Cunanan C
    J Clin Psychopharmacol; 2003 Apr; 23(2):176-81. PubMed ID: 12640219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divalproex extended-release in acute bipolar II depression.
    Wang PW; Nowakowska C; Chandler RA; Hill SJ; Nam JY; Culver JL; Keller KL; Ketter TA
    J Affect Disord; 2010 Jul; 124(1-2):170-3. PubMed ID: 19923006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Reed RC; Cavanaugh JH
    J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
    Reed RC; Dutta S
    Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
    Dutta S; Reed RC; Cavanaugh JH
    Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium.
    Pierre-Louis SJ; Brannegan RT; Evans AT
    Clin Neurol Neurosurg; 2009 Jun; 111(5):437-41. PubMed ID: 19181439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials.
    Smith MC; Centorrino F; Welge JA; Collins MA
    Epilepsy Behav; 2004 Oct; 5(5):746-51. PubMed ID: 15380129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
    Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
    Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release divalproex sodium for mood stabilization.
    Stoner SC; Dubisar BM; Lea JW; Marken PA; Ramlatchman LV; Reynolds JB
    Pharmacotherapy; 2004 Sep; 24(9):1147-53. PubMed ID: 15460175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of oral loading of divalproex sodium in the treatment of acute mania.
    Martinez JM; Russell JM; Hirschfeld RM
    Depress Anxiety; 1998; 7(2):83-6. PubMed ID: 9614597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy.
    Lunde JL; Nelson RE; Storandt HF
    Pharmacotherapy; 2007 Aug; 27(8):1202-5. PubMed ID: 17655519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
    Yasui-Furukori N; Saito M; Nakagami T; Niioka T; Sato Y; Fujii A; Kaneko S
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):308-12. PubMed ID: 17472600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-equivalence of bioavailability between generic and branded form of sodium valproate.
    Dhanaraj M; Jayavelu A
    Neurol India; 2004 Sep; 52(3):398. PubMed ID: 15472447
    [No Abstract]   [Full Text] [Related]  

  • 20. Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium.
    Dutta S; Reed RC
    Am J Health Syst Pharm; 2006 May; 63(10):904-6. PubMed ID: 16675645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.